Lopressor: Advanced Beta-Blocker Therapy for Cardiovascular Control
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.76 | $45.58 (0%) | 🛒 Add to cart |
| 90 | $0.64 | $68.37 $57.62 (16%) | 🛒 Add to cart |
| 120 | $0.58 | $91.16 $69.66 (24%) | 🛒 Add to cart |
| 180 | $0.53 | $136.74 $95.46 (30%) | 🛒 Add to cart |
| 270 | $0.49 | $205.11 $131.58 (36%) | 🛒 Add to cart |
| 360 | $0.47
Best per pill | $273.48 $168.56 (38%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.59 | $35.26 (0%) | 🛒 Add to cart |
| 90 | $0.46 | $52.89 $41.28 (22%) | 🛒 Add to cart |
| 120 | $0.39 | $70.52 $47.30 (33%) | 🛒 Add to cart |
| 180 | $0.32
Best per pill | $105.78 $58.48 (45%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.44 | $39.56 (0%) | 🛒 Add to cart |
| 120 | $0.39 | $52.75 $47.30 (10%) | 🛒 Add to cart |
| 180 | $0.34 | $79.12 $61.92 (22%) | 🛒 Add to cart |
| 270 | $0.32 | $118.68 $85.14 (28%) | 🛒 Add to cart |
| 360 | $0.30
Best per pill | $158.24 $107.50 (32%) | 🛒 Add to cart |
Synonyms | |||
Lopressor (metoprolol tartrate) is a cardioselective beta-1 adrenergic receptor blocking agent indicated for the management of hypertension, angina pectoris, and hemodynamic stability following myocardial infarction. As a foundational therapeutic in cardiovascular medicine, it modulates sympathetic nervous system activity, reducing heart rate, myocardial contractility, and conduction velocity. Its established efficacy and favorable pharmacokinetic profile make it a first-line option in evidence-based treatment protocols for a range of cardiovascular conditions, offering clinicians a reliable tool for long-term patient management.
Features
- Contains metoprolol tartrate as the active pharmaceutical ingredient
- Available in 25 mg, 50 mg, and 100 mg immediate-release tablet formulations
- Exhibits relative beta-1 cardioselectivity at therapeutic doses
- Demonstrates linear pharmacokinetics with approximately 50% oral bioavailability
- Peak plasma concentrations achieved within 1–2 hours post-administration
- Plasma protein binding is approximately 12%
- Metabolized primarily via CYP2D6 hepatic pathway
- Elimination half-life ranges from 3 to 7 hours in most patients
Benefits
- Effectively lowers systolic and diastolic blood pressure through reduced cardiac output
- Decreases myocardial oxygen demand, providing antianginal protection
- Improves survival rates when administered early in acute myocardial infarction
- Reduces mortality in chronic heart failure when used with standard therapy
- Helps control heart rate in atrial fibrillation and tachyarrhythmias
- May prevent migraine headaches through vascular stabilization
Common use
Lopressor is predominantly prescribed for the management of essential hypertension, either as monotherapy or in combination with other antihypertensive agents. It is widely utilized for long-term prophylaxis of angina pectoris, particularly in patients with exertional or stress-induced symptoms. In post-myocardial infarction care, it is administered to stabilize cardiac rhythm, limit infarct size, and reduce the risk of reinfarction. Off-label applications include rate control in supraventricular tachycardias, symptomatic treatment of hyperthyroidism, and prophylaxis of migraine headaches. Its use in heart failure with reduced ejection fraction follows specific titration protocols under careful clinical supervision.
Dosage and direction
For hypertension management, initial dosing typically begins with 25–50 mg twice daily, with titration upward at weekly intervals based on therapeutic response. Maximum recommended daily dosage is 400 mg divided into two administrations. For angina pectoris, starting dose is 50 mg twice daily, potentially increased to 100–200 mg twice daily depending on clinical effect. In acute myocardial infarction, early intravenous administration may be followed by oral therapy at 50 mg every 6 hours for 48 hours, then transitioning to 100 mg twice daily. Tablets should be taken with or immediately following meals to enhance bioavailability and minimize peak concentration variations. Dosage adjustments are necessary in hepatic impairment and in poor CYP2D6 metabolizers.
Precautions
Abrupt discontinuation of Lopressor should be avoided due to risk of rebound hypertension, tachycardia, and angina exacerbation. Gradual tapering over 1–2 weeks is recommended under physician supervision. Caution is advised in patients with compensated heart failure, bronchospastic diseases, diabetes mellitus, and thyrotoxicosis. Hepatic function should be monitored periodically during long-term therapy. Patients should be advised about potential impaired reaction time affecting driving or machinery operation. Regular monitoring of heart rate, blood pressure, and ECG parameters is essential during dose titration. Use during pregnancy requires careful risk-benefit assessment due to potential fetal bradycardia and hypoglycemia.
Contraindications
Lopressor is contraindicated in patients with severe bradycardia (heart rate <45–50 bpm), second- or third-degree heart block without functioning pacemaker, cardiogenic shock, decompensated heart failure, and sick sinus syndrome. Additional absolute contraindications include hypersensitivity to metoprolol or other beta-blockers, severe peripheral arterial circulatory disorders, and pheochromocytoma (unless used with alpha-blockade). Concurrent administration with flutter/fibrillation and concomitant use with certain calcium channel blockers (verapamil, diltiazem) is contraindicated due to additive negative chronotropic and inotropic effects.
Possible side effect
Common adverse reactions (≥1%) include fatigue (10%), dizziness (10%), depression (5%), diarrhea (5%), pruritus (5%), and bradycardia (3%). Less frequent effects include dyspnea, cold extremities, insomnia, nightmares, and bronchospasm. Serious but rare adverse events include heart block, exacerbation of heart failure, hypotension, masking of hypoglycemia symptoms, and Raynaud’s phenomenon. Dermatological reactions such as psoriasisiform eruptions or exacerbation of psoriasis have been reported. Reversible alopecia and Peyronie’s disease represent very rare associations. Most side effects are dose-dependent and often diminish with continued therapy or dosage reduction.
Drug interaction
Lopressor exhibits significant interactions with CYP2D6 inhibitors including fluoxetine, paroxetine, and quinidine, potentially increasing metoprolol concentrations. Concurrent use with other negative chronotropic agents (digoxin, diltiazem, verapamil) may produce excessive bradycardia. Concomitant administration with clonidine may potentiate rebound hypertension upon withdrawal. Nonsteroidal anti-inflammatory drugs may attenuate antihypertensive effects. Insulin and oral hypoglycemics require dosage adjustment due to masked hypoglycemia symptoms. Combination with other antihypertensives may produce additive hypotensive effects. Calcium channel blockers of the dihydropyridine class may require dosage modification when co-administered.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent timing of doses is important for maintaining stable plasma concentrations and therapeutic effect, particularly in angina management. Healthcare providers should educate patients about the importance of adherence and develop strategies to minimize missed doses in elderly patients or those with complex medication regimens.
Overdose
Metoprolol overdose primarily manifests as bradycardia, hypotension, bronchospasm, acute heart failure, and hypoglycemia. Severe cases may progress to cardiogenic shock, heart block, and cardiac arrest. Management includes gastric lavage if presentation is early, followed by activated charcoal administration. Cardiovascular support with atropine for bradycardia and vasopressors (norepinephrine, epinephrine) for hypotension may be necessary. Glucagon has been used successfully to reverse myocardial depression. Temporary cardiac pacing may be required for profound bradycardia or heart block. Bronchospasm should be treated with beta-2 agonists. Hemodialysis is not effective due to extensive protein binding.
Storage
Lopressor tablets should be stored at controlled room temperature (20–25°C or 68–77°F) in their original container, protected from light and moisture. Keep tightly closed and away from excessive heat or humidity. Do not store in bathroom cabinets where moisture levels fluctuate. Keep out of reach of children and pets. Do not use tablets that show signs of discoloration, cracking, or other physical deterioration. Proper disposal of unused medication should follow local regulations, typically through medication take-back programs rather than flushing or household trash disposal.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Lopressor is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual patient response may vary, and therapeutic decisions should be based on clinical assessment of the specific patient. The prescribing physician should be consulted for complete information regarding indications, dosage, warnings, and precautions. Never adjust dosage or discontinue medication without medical supervision.
Reviews
Clinical studies demonstrate Lopressor’s efficacy in reducing blood pressure by 10–15 mmHg systolic and 8–10 mmHg diastolic in hypertensive patients. Angina studies show significant reduction in attack frequency and nitrate consumption. The Gothenburg Metoprolol Trial and subsequent MIAMI trial established a 36% reduction in mortality when administered early after myocardial infarction. MERIT-HF trial demonstrated 34% mortality reduction in heart failure patients. Patient satisfaction surveys indicate good tolerability with appropriate dose titration, though some report fatigue and sexual dysfunction. Long-term follow-up studies confirm maintained efficacy with continued therapy over years.